BioPharma Dive
1,422 FOLLOWERS
BioPharma Dive is a leading industry publication providing in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing, and M&A to research partnerships.
BioPharma Dive
14h ago
The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines. ..read more
BioPharma Dive
16h ago
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian ..read more
BioPharma Dive
16h ago
The layoffs will impact some 2,200 employees, the company said, as it repositions ahead of looming patent expirations for top-selling products ..read more
BioPharma Dive
22h ago
“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said ..read more
BioPharma Dive
2d ago
While the company is eager to diversify, CEO Chris Viehbacher said that in the near-term any dealmaking would likely focus on collaborations and early-stage assets ..read more
BioPharma Dive
2d ago
An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes ..read more
BioPharma Dive
2d ago
First quarter sales of Zurzuvae doubled consensus estimates, though analysts are skeptical whether the better-than-expected launch will continue ..read more
BioPharma Dive
2d ago
Growing demand has convinced Biogen that it's worth expanding the sales force around Leqembi by 30 ..read more
BioPharma Dive
2d ago
In this three-part podcast series, hear from seasoned experts from Allucent as they discuss a range of topics, including how small and mid-sized companies can take a more strategic approach to pharmacovigilance, a regulatory & development roadmap for ADCs and RDCs, and pre-MAA/NDA inspection readiness ..read more
BioPharma Dive
2d ago
The mRNA vaccine maker, which has lost most of its value since early 2021, is undergoing an “organizational redesign” that will involve the elimination of 150 positions ..read more